Encompass Health Corporation (EHC) vs Halozyme Therapeutics, Inc. (HALO)
A side-by-side comparison of Encompass Health Corporation and Halozyme Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EHC
Encompass Health Corporation
$123.94HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
HALO
Halozyme Therapeutics, Inc.
$108.12HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT
Total return — EHC vs HALO
growth of $100 · dividends reinvested · last 10yEHC +326.5% (+15.6%/yr)HALO +779.9% (+24.3%/yr)HALO compounded faster over this window
EHC HALO
EHC vs HALO: by the numbers
- •HALO is the larger company ($12.82B vs $12.29B market cap).
- •EHC trades at the lower trailing earnings multiple (20.19 vs 32.27 P/E), one valuation lens rather than an overall verdict.
- •HALO converts more revenue to profit (24.86% vs 10.01% net margin).
- •HALO grew revenue faster over the past five years (32.18% vs 4.81% CAGR).
- •EHC pays a dividend (0.63% yield), while HALO has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | EHC | HALO |
|---|---|---|
| P/E ratio | 20.19 | 32.27 |
| Forward P/E | 20.27 | 12.85 |
| PEG ratio | 1.42 | 1.40 |
| P/S ratio | 1.98 | 7.71 |
| P/B ratio | 4.73 | 89.34 |
| EV / EBITDA | 10.27 | 14.04 |
| FCF yield | 3.36% | 6.29% |
Profitability
| Metric | EHC | HALO |
|---|---|---|
| Gross margin | 95.71% | 78.18% |
| Operating margin | 18.00% | 56.77% |
| Net margin | 10.01% | 24.86% |
| ROE | 23.91% | 288.13% |
| ROIC | 13.42% | 27.42% |
Dividends
| Metric | EHC | HALO |
|---|---|---|
| Dividend yield | 0.63% | N/A |
| Payout ratio | 12.38% | N/A |
Growth (annualized)
| Metric | EHC | HALO |
|---|---|---|
| Revenue CAGR (5Y) | 4.81% | 32.18% |
| EPS CAGR (5Y) | 14.39% | 22.68% |
| FCF CAGR (5Y) | 0.28% | 40.08% |
| Total return CAGR (5Y) | 17.12% | 22.18% |
Frequently asked
- Which has the lower trailing P/E, EHC or HALO?
- EHC has the lower trailing P/E: EHC trades at 20.19 and HALO at 32.27. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, EHC or HALO?
- Over the past five years, HALO grew revenue faster — EHC at a 4.81% CAGR versus HALO at 32.18%.
- Does EHC or HALO pay a bigger dividend?
- EHC pays a dividend (0.63% yield), while HALO has no payments in the available dividend history.
- Is EHC or HALO more profitable?
- HALO runs the higher net margin — EHC at 10.01% versus HALO at 24.86%.
- How have EHC and HALO total returns compared?
- Over the past 10 years, EHC delivered 15.79% and HALO delivered 24.30% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Encompass Health P/E ratioHalozyme Therapeutics P/E ratioEncompass Health dividend yieldEncompass Health ROEHalozyme Therapeutics ROEEncompass Health operating marginHalozyme Therapeutics operating marginEncompass Health revenue growthHalozyme Therapeutics revenue growthEncompass Health free cash flowHalozyme Therapeutics free cash flow
Encompass Health & Halozyme Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.